Pharmacological and electrophysiological characterization of AZSMO‐23, an activator of the hERG K+ channel
- 10 April 2015
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 172 (12) , 3112-3125
Abstract
Background and Purpose: We aimed to characterize the pharmacology and electrophysiology of N‐[3‐(1H‐benzimidazol‐2‐yl)‐4‐chloro‐phenyl]pyridine‐3‐carboxamide (AZSMO‐23), an activator of the human ether‐a‐go‐go‐related gene (hERG)‐encoded K+ channel (Kv11.1).Experimental Approach: Automated electrophysiology was used to study the pharmacology of AZSMO‐23 on wild‐type (WT), Y652A, F656T or G628C/S631C hERG, and on other cardiac ion channels. Its mechanism of action was characterized with conventional electrophysiology.Key Results: AZSMO‐23 activated WT hERG pre‐pulse and tail current with EC50 values of 28.6 and 11.2 μM respectively. At 100 μM, pre‐pulse current at +40 mV was increased by 952 ± 41% and tail current at −30 mV by 238 ± 13% compared with vehicle values. The primary mechanism for this effect was a 74.5 mV depolarizing shift in the voltage dependence of inactivation, without any shift in the voltage dependence of activation. Structure–activity relationships for this effect were remarkably subtle, with close analogues of AZSMO‐23 acting as hERG inhibitors. AZSMO‐23 blocked the mutant channel, hERG Y652A, but against another mutant channel, hERG F656T, its activator activity was enhanced. It inhibited activity of the G628C/S631C non‐inactivating hERG mutant channel. AZSMO‐23 was not hERG selective, as it blocked hKv4.3‐hKChIP2.2, hCav3.2 and hKv1.5 and activated hCav1.2/β2/α2δ channels.Conclusion and Implications: The activity of AZSMO‐23 and those of its close analogues suggest these compounds may be of value to elucidate the mechanism of type 2 hERG activators to better understand the pharmacology of this area from both a safety perspective and in relation to treatment of congenital long QT syndrome.Keywords
This publication has 31 references indexed in Scilit:
- The Concise Guide to PHARMACOLOGY 2013/14: Ion ChannelsBritish Journal of Pharmacology, 2013
- Molecular Determinants for Activation of Human Ether-à-go-go-related Gene 1 Potassium Channels by 3-Nitro-N-(4-phenoxyphenyl) BenzamideMolecular Pharmacology, 2011
- Pharmacological Removal of Human Ether-à-go-go-Related Gene Potassium Channel Inactivation by 3-Nitro-N-(4-phenoxyphenyl) Benzamide (ICA-105574)Molecular Pharmacology, 2010
- Characterisation of an activator of the hERG-encoded potassium channelJournal of Pharmacological and Toxicological Methods, 2008
- Biophysical Characterization of the New Human Ether-A-Go-Go-Related Gene Channel Opener NS3623 [N-(4-Bromo-2-(1H-tetrazol-5-yl)-phenyl)-N′-(3′-trifluoromethylphenyl)urea]Molecular Pharmacology, 2006
- Optimisation and validation of a medium-throughput electrophysiology-based hERG assay using IonWorks™ HTJournal of Pharmacological and Toxicological Methods, 2006
- Population Patch Clamp Improves Data Consistency and Success Rates in the Measurement of Ionic CurrentsSLAS Discovery, 2006
- Mechanism of Action of a Novel Human ether-a-go-go-Related Gene Channel ActivatorMolecular Pharmacology, 2006
- Physicochemical Features of the hERG Channel Drug Binding SiteJournal of Biological Chemistry, 2004
- Inactivation of the sodium channel. I. Sodium current experiments.Journal of General Physiology, 1977